@article{ref1,
title="Emerging therapeutic options for the management of COPD",
journal="Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine",
year="2013",
author="Reid, D.J. and Pham, N.T.",
volume="7",
number="1",
pages="7-15",
abstract="Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third by 2020. COPD is characterized by chronic airflow limitation caused by airway inflammation and parenchymal destruction that is usually progressive. Inhaled bronchodilators continue to be the mainstay of the current management of COPD. Safety and efficacy data of the recently approved medications including aclidinium, glycopyrronium, roflumilast, and indacaterol are reviewed here. © the author(s), publisher and licensee Libertas Academica Ltd.<p /><p>Language: en</p>",
language="en",
issn="1179-5484",
doi="10.4137/CCRPM.S8140",
url="http://dx.doi.org/10.4137/CCRPM.S8140"
}